Dr. Karen M. Huhn
- Gender: Female
- Sole propriator: No
- NPI: 1053380386
Dr. Karen M. Huhn MD
Dermatopathologist
She is located at 133 Brookline Avenue in Boston, MA 02215. Can help patients with the following: Benign Tumor, Bug Bites, Cyst, Infarction, Skin Biopsy. Her National Provider Identifier (NPI) number is 1053380386. Appointment can be made via the phone number (617) 421-2340. She is affiliated with 1 practices.
Conditions treated
Dr. Karen M. Huhn, being an dermatopathologist, treats the following conditions. Please be advised that this list may not be complete. For the full list of conditions treated, consult directly with Dr. Karen M. Huhn.
- Benign Tumor
- Bug Bites
- Cyst
- Infarction
- Skin Biopsy
Additional Specialities
- Pathologist
Looking for more Dermatopathologists?
- Gender: Female
- Address: 1542 Tulane Avenue New Orleans, 70112, LA
- Gender: Male
- Address: 3512 Old Montgomery Highway Birmingham, 35209, AL
- Gender: Female
- Address: 658 Grassmere Park Nashville, 37211, TN
- Gender: Female
- Address: 15 York Street New Haven, 6510, CT
- Gender: Male
- Address: 7835 Paragon Road Dayton, 45459, OH
- Gender: Male
- Address: 6825 16th Street Northwest Washington, 20306, DC
- Gender: Male
- Address: 3550 Independence Drive Birmingham, 35209, AL
- Gender: Male
- Address: Suite 240 419 West Redwood Street Baltimore, 21201, MD
- Gender: Male
- Address: 125 North Robertson Boulevard Beverly Hills, 90211, CA
- Gender: Male
- Address: Building 3 1141 Whitney Avenue Gretna, 70056, LA
Questions & Answers
Does Dr. Karen M. Huhn accept insurance?
Unfortunately we don't have any information if Dr. Karen M. Huhn accepts insurance.
Where can you meet with Dr. Karen M. Huhn?
Dr. Karen M. Huhn's office is located at 133 Brookline Avenue in Boston, MA 02215.
What conditions does Dr. Karen M. Huhn treat?
Dr. Karen M. Huhn provides treatment for Benign Tumor, Bug Bites, Cyst, Infarction, Skin Biopsy.
Does Dr. Karen M. Huhn have affiliation with practices?
Dr. Karen M. Huhn is affiliated with Kenmore - Harvard Vanguard.